Page last updated: 2024-11-12

3-deacetylvecuronium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-deacetylvecuronium: RN given refers to parent cpd (2beta,3alpha,5alpha,16beta,17beta)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11849104
CHEBI ID187362
MeSH IDM0138188

Synonyms (16)

Synonym
3-hydroxyvecuronium
74041-85-3
CHEBI:187362
[(2s,3s,5s,8r,9s,10s,13s,14s,16s,17r)-3-hydroxy-10,13-dimethyl-16-(1-methylpiperidin-1-ium-1-yl)-2-piperidin-1-yl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate
3-deacetylvecuronium
3-desacetylvecuronium
unii-7gjt8823h1
7gjt8823h1 ,
piperidinium, 1-((2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-(1-piperidinyl)androstan-16-yl)-1-methyl-
desacetylvecuronium
piperidinium, 1-((2.beta.,3.alpha.,5.alpha.,16.beta.,17.beta.)-17-(acetyloxy)-3-hydroxy-2-(1-piperidinyl)androstan-16-yl)-1-methyl-
3-deacetylvecuronium cation
1-(17.beta.-(acetyloxy)-3.alpha.-hydroxy-2.beta.-(piperidin-1-yl)-5.alpha.-androstan-16.beta.-yl)-1-methylpiperidinium
vecuronium bromide impurity c [ep impurity]
org-7268 cation
Q27268251

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" In combination with data from subfractionation studies the results indicate that the pharmacokinetic analysis of the hepatic disposition of steroidal muscle relaxants may be used to evaluate actual transport phenomena participating in the hepatic disposition of these drugs."( Pharmacokinetics of steroidal muscle relaxants in isolated perfused rat liver.
Meijer, DK; Mol, WE; Oosting, R; Paanakker, JE; Rombout, F; Scaf, AH, 1992
)
0.28
" In cats with renal failure, 3-desacetylvecuronium pharmacokinetic and pharmacodynamic variables did not differ from those in control cats."( Pharmacokinetics, neuromuscular effects, and biodisposition of 3-desacetylvecuronium (Org 7268) in cats.
Agoston, S; Caldwell, JE; Gruenke, LD; Khuenl-Brady, KS; Miller, RD; Segredo, V; Sharma, ML; Shin, YS, 1991
)
0.28
"kg-1; a longer terminal elimination half-life 116 (44-672) vs."( The pharmacodynamics and pharmacokinetics of the metabolite 3-desacetylvecuronium (ORG 7268) and its parent compound, vecuronium, in human volunteers.
Caldwell, JE; Fisher, DM; Gruenke, LD; McLoughlin, C; Miller, RD; Segredo, V; Sharma, ML; Szenohradszky, J; Wright, PM, 1994
)
0.29
" In this study, the pharmacokinetic behavior (n = 7) of this metabolite and the pharmacokinetic/pharmacodynamic (PK/PD) relationship of rapacuronium (n = 10) and Org 9488 (n = 7) were investigated in humans."( Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488).
Proost, JH; Schiere, S; Schuringa, M; Wierda, JM, 1999
)
0.3
" Pharmacokinetic and pharmacodynamic modeling was used to characterize the disposition of vecuronium and patient responses to it in the two groups."( Influence of chronic phenytoin administration on the pharmacokinetics and pharmacodynamics of vecuronium.
Caldwell, JE; McCarthy, G; Sharma, ML; Szenohradszky, J; Wright, PM, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
" Dose-response relationships were established for each substance alone and for combinations of vecuronium with its metabolites."( Antagonism of vecuronium by one of its metabolites in vitro.
Khuenl-Brady, KS; Koller, J; Mair, P, 1992
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (18.18)18.7374
1990's7 (63.64)18.2507
2000's1 (9.09)29.6817
2010's1 (9.09)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.05 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]